Triclosan
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Triclosan: From an Unspecified Topical Antimicrobial Use to Acne
One-Sentence Summary
Triclosan is a broad-spectrum antibacterial agent that is currently registered in Singapore as a single-ingredient lotion product (a bath oil), although no approved indication text is on record. The TxGNN model predicts it may be effective for acne, but there are 0 clinical trials and only 1 indirectly related publication (a review about a different disease, hidradenitis suppurativa) supporting this direction. The evidence is weak, and the high model score is not backed by direct clinical data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 97.38% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, triclosan is a broad-spectrum antibacterial that inhibits bacterial enoyl-acyl carrier protein reductase (FabI). It has activity against Cutibacterium acnes and Staphylococcus species.
Because bacterial colonisation contributes to acne, this gives a plausible but indirect link between the drug and the predicted indication. This is only a mechanistic hypothesis, however. The single publication retrieved concerns treatment frameworks for hidradenitis suppurativa (acne inversa), a different disease, and does not evaluate triclosan.
The high TxGNN score (97.38%) should therefore be read as a model signal, not as confirmation of clinical benefit.
Clinical Trial Evidence
Currently no related clinical trials registered for acne.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30176066 | 2019 | Systematic review | J Eur Acad Dermatol Venereol | Systematic review and consensus recommendations for hidradenitis suppurativa/acne inversa management. It does not evaluate triclosan and concerns a different disease, so it offers only indirect context. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11468P | QV FLARE UP BATH OIL | Lotion | Not stated |
Safety Considerations
- Contraindications flagged by the knowledge graph (not from label text): The TxGNN knowledge graph links triclosan to contraindication edges for epilepsy, sudden cardiac arrest, heart conduction disease and respiratory failure. These are model-derived associations and should be verified against official labelling.
- Thyroid and endocrine signals from the literature: Studies reviewed for the thyroid-related prediction examine triclosan as an exposure that may disrupt thyroid hormone homeostasis. These include pregnancy cohorts, a toothpaste-use study and animal work showing reduced thyroid hormone levels. They indicate a potential safety concern, not a therapeutic benefit.
- Drug interactions: No interaction records were found.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The acne prediction rests on a plausible antibacterial mechanism but has no direct clinical trial or literature support. The only retrieved publication addresses a different disease. In addition, the local registration lacks indication and label safety data, and triclosan carries endocrine/thyroid safety signals in the literature.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which are currently missing and block safety screening
- Mechanism of action data confirmed from DrugBank
- Direct evidence of triclosan efficacy in acne (clinical trials or relevant studies)
- A formal safety assessment addressing the thyroid and endocrine-disruption signals
- Confirmation of the approved indication and route of use for the registered Singapore product
Other Predicted Indications (Brief Notes)
Other predictions were also reviewed, and none currently supports advancing:
- Scalp dermatosis (score 94.15%, L4, Hold): One retrospective safety study (NCT05105139, n=90) of Sebryl/Sebryl Plus products in seborrheic dermatitis and scalp psoriasis. It does not confirm triclosan as the active ingredient and did not assess efficacy.
- Thyroid gland disease (score 88.04%, L4, Hold): The literature treats triclosan as a potential thyroid disruptor, not a treatment. This is a safety concern and argues against repurposing.
- Familial adrenal hypoplasia with absent pituitary LH, PAGOD syndrome, elevated plasma zinc, primary release disorder of platelets, pseudo-von Willebrand disease, multiple endocrine neoplasia, familial pityriasis rubra pilaris (all L5, Hold): Prediction-only signals with no plausible mechanism or supporting evidence.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.